Polygenic risk for triglyceride levels in the presence of a high impact rare variant.

"Declarations Ethics approval and consent to participateAll participants provided written informed consent and the study was approved by the local research ethics boards of hospitals affiliated with the University of Toronto (the Centre for Addiction and Mental Health and University Health Network) where participants were ascertained (e.g., the Dalglish Family 22q Clinic at the Toronto General Hospital), with referrals originating from generalists and specialists. All methods were carried out in accordance with relevant guidelines and regulations. Consent for publicationNot applicable. Competing interestsRobert A. Hegele reports consulting fees from Acasti, Aegerion, Akcea/Ionis, Amgen, Arrowhead, Boston Heart, HLS Therapeutics, Pfizer, Novartis, Regeneron, Sanofi and Ultragenyx. None of the other authors have any conflicts to report. Competing interests Robert A. Hegele reports consulting fees from Acasti, Aegerion, Akcea/Ionis, Amgen, Arrowhead, Boston Heart, HLS Therapeutics, Pfizer, Novartis, Regeneron, Sanofi and Ultragenyx. None of the other authors have any conflicts to report."

"Funding This work was supported by the Canadian Institutes of Health Research (CIHR) (PJT-169161, PJT-148924). ASB holds the Dalglish Chair in 22q11.2 Deletion Syndrome at the University Health Network and University of Toronto. SY was supported by a Canadian Institutes of Health Research Canada Graduate Scholarship Master’s and the University of Toronto Joseph Wong Memorial Graduate Award. Some genome sequencing was originally done as part of the International 22q11.2DS Brain and Behavior Consortium and National Institute of Mental Health grant U01MH0101720, with recalling of sequencing data supported by a McLaughlin Centre Accelerator Grant. "